Biology subjects

Tokheim, C.

Publications and source records attributed to Tokheim, C..

9 recordsLinked to original sources

bioRxiv2022

Charting the Spatial Landscape of Cancer Hallmarks

Tumors are complex ecosystems with dozens of interacting cell types. The concept of Cancer Hallmarks distills this complexity into a set of underlying principles that govern tumor growth. Here, we exploit this abstraction to explore the physical distribution of Cancer Hallmarks across 63 primary untreated tumors from 10 cancer types using spatial transcriptomics. We show that Hallmark activity is spatially organized-with 7 out of 13 Hallmarks consistently more active in cancer cells than within the non-cancerous tumor microenvironment (TME). The opposite is true for the remaining six Hallmarks. Additionally, we discovered that genomic distance between tumor subclones correlates with differences in Cancer Hallmark activity, even leading to clone-Hallmark specialization in some cases. Finally, we demonstrate interdependent relationships between Cancer Hallmarks at the junctions of TME and cancer compartments. In conclusion, including the spatial dimension, particularly through the lens of Cancer Hallmarks, can improve our understanding of tumor ecology. SignificanceWe explored Cancer Hallmarks in 63 primary untreated tumors from 10 cancer types using spatial transcriptomics. This study unveiled spatial patterns in Hallmark activity, with some being more active in cancer cells and others in the non-cancerous tumor environment. Genomic distance impacted Hallmark activity, and we identified interdependencies at the TME-cancer junctions, improving our understanding of tumor ecology.

cancer biology↗

bioRxiv2021

Data-driven discovery of targets for bipotent anticancer drugs identifies Estrogen Related Receptor Alpha

Drugs that kill tumors through multiple mechanisms have potential for broad clinical benefits, with a reduced propensity to resistance. We developed BipotentR, a computational approach to find cancer-cell-specific regulators that simultaneously modulate tumor immunity and another oncogenic pathway. Using tumor metabolism as proof-of-principle, BipotentR identified 38 candidate immune-metabolic regulators by combining epigenomes with bulk and single-cell tumor transcriptomes from patients. Inhibition of top candidate ESRRA (Estrogen Related Receptor Alpha) killed tumors by direct effects on energy metabolism and two immune mechanisms: (i) cytokine induction, causing proinflammatory macrophage polarization (ii) antigen-presentation stimulation, recruiting CD8+T cells into tumors. ESRRA is activated in immune-suppressive and immunotherapy-resistant tumors of many types, suggesting broad clinical relevance. We also applied BipotentR to angiogenesis and growth-suppressor pathways, demonstrating a widely applicable approach to identify drug targets that act simultaneously through multiple mechanisms. BipotentR is publicly available at http://bipotentr.dfci.harvard.edu/. One-Sentence SummaryBipotentR identifies targets for bipotent anticancer drugs, as shown by the energy and immune effects of ESRRA inhibition.

cancer biology↗

bioRxiv2021

Machine learning modeling of protein-intrinsic features predicts tractability of targeted protein degradation

Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cells endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed "degradability", is largely unknown. Recent systematic studies to map the degradable kinome have shown differences in degradation between kinases with similar drug-target engagement, suggesting yet unknown factors influencing degradability. We therefore developed a machine learning model, MAPD (Model-based Analysis of Protein Degradability), to predict degradability from protein features that encompass post-translational modifications, protein stability, protein expression and protein-protein interactions. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds (auPRC=0.759) and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By structural modeling, we found that E2-accessible ubiquitination sites, but not lysine residues in general, are particularly associated with kinase degradability. Finally, we extended MAPD predictions to the entire proteome to find 964 disease-causing proteins, including 278 cancer genes, that may be tractable to TPD drug development.

bioinformatics↗

bioRxiv2020

In Vivo CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target

Despite remarkable clinical efficacies of immune checkpoint blockade (ICB) in cancer treatment, ICB benefits in triple-negative breast cancer (TNBC) remain limited. Through pooled in vivo CRISPR knockout (KO) screens in syngeneic TNBC mouse models, we found that inhibition of the E3 ubiquitin ligase Cop1 in cancer cells decreases the secretion of macrophage-associated chemokines, reduces tumor macrophage infiltration, and shows synergy in anti-tumor immunity with ICB. Transcriptomics, epigenomics, and proteomics analyses revealed Cop1 functions through proteasomal degradation of the C/ebp{delta} protein. Cop1 substrate Trib2 functions as a scaffold linking Cop1 and C/ebp{delta}, which leads to polyubiquitination of C/ebp{delta}. Cop1 inhibition stabilizes C/ebp{delta} to suppress the expression of macrophage chemoattractant genes. Our integrated approach implicates Cop1 as a target for improving cancer immunotherapy efficacy by regulating chemokine secretion and macrophage levels in the TNBC tumor microenvironment. HighlightsO_LILarge-scale in vivo CRISPR screens identify new immune targets regulating the tumor microenvironment C_LIO_LICop1 knockout in cancer cells enhances anti-tumor immunity C_LIO_LICop1 modulates chemokine secretion and macrophage infiltration into tumors C_LIO_LICop1 targets C/ebp{delta} degradation via Trib2 and influences ICB response C_LI

cancer biology↗

bioRxiv2019

OpenCRAVAT, an open source collaborative platform for the annotation of human genetic variation

PURPOSEThe modern researcher is confronted with hundreds of published methods to interpret genetic variants. There are databases of genes and variants, phenotype-genotype relationships, algorithms that score and rank genes, and in silico variant effect prediction tools. Because variant prioritization is a multi-factorial problem, a welcome development in the field has been the emergence of decision support frameworks, which make it easier to integrate multiple resources in an interactive environment. Current decision support frameworks are typically limited by closed proprietary architectures, access to a restricted set of tools, lack of customizability, web dependencies that expose protected data, or limited scalability.\n\nMETHODSWe present OpenCRAVAT, a new open source, scalable decision support system for variant and gene prioritization. We have designed the resource catalog to be open and modular to maximize community and developer involvement, and as a result the catalog is being actively developed and growing every month. Resources made available via the store are well-suited for analysis of cancer, as well as Mendelian and complex diseases.\n\nRESULTSOpenCRAVAT offers both command line utility and dynamic GUI, allowing users to install with a single command, easily download tools from an extensive resource catalog, create customized pipelines, and explore results in a richly detailed viewing environment. We present several case studies to illustrate the design of custom workflows to prioritize genes and variants.\n\nCONCLUSIONOpenCRAVAT is distinguished from similar tools by its capabilities to access and integrate an unprecedented amount of diverse data resources and computational prediction methods, which span germline, somatic, common, rare, coding and non-coding variants. OpenCRAVAT is freely available at https://opencravat.org

bioinformatics↗

bioRxiv2019

High-throughput prediction of MHC Class I and Class II neoantigens with MHCnuggets

Computational prediction of binding between neoantigen peptides and major histocompatibility complex (MHC) proteins is an emerging biomarker for predicting patient response to cancer immunotherapy. Current neoantigen predictors focus on in silico estimation of MHC binding affinity and are limited by low positive predictive value for actual peptide presentation, inadequate support for rare MHC alleles and poor scalability to high-throughput data sets. To address these limitations, we developed MHCnuggets, a deep neural network method to predict peptide-MHC binding. MHCnuggets is the only method to handle binding prediction for common or rare alleles of MHC Class I or II, with a single neural network architecture. Using a long short-term memory network (LSTM), MHCnuggets accepts peptides of variable length and is capable of faster performance than other methods. When compared to methods that integrate binding affinity and HLAp data from mass spectrometry, MHCnuggets yields a fourfold increase in positive predictive value on independent MHC-bound peptide (HLAp) data. We applied MHCnuggets to 26 cancer types in TCGA, processing 26.3 million allele-peptide comparisons in under 2.3 hours, yielding 101,326 unique candidate immunogenic missense mutations (IMMs). Predicted-IMM hotspots occurred in 38 genes, including 24 driver genes. Predicted-IMM load was significantly associated with increased immune cell infiltration (p<2e-16) including CD8+ T cells. Notably, only 0.16% of predicted immunogenic missense mutations were observed in >2 patients, with 61.7% of these derived from driver mutations. Our results provide a new method for neoantigen prediction with high performance characteristics and demonstrate its utility in large data sets across human cancers.\n\nSynopsisWe developed a new in silico predictor of Major Histocompatibility Complex (MHC) ligand binding and demonstrated its utility to assess potential neoantigens and immunogenic missense mutations (IMMs) in 6613 TCGA patients.

immunology↗

bioRxiv2018

Enhanced context reveals the scope of somatic missense mutations driving human cancers

Large-scale cancer sequencing studies of patient cohorts have statistically implicated many genes driving cancer growth and progression, and their identification has yielded substantial translational impact. However, a remaining challenge is to increase the resolution of driver prediction from the gene level to the mutation level, because mutation-level predictions are more closely aligned with the goal of precision cancer medicine. Here we present CHASMplus, a computational method, that is uniquely capable of identifying driver missense mutations, including those specific to a cancer type, as evidenced by significantly superior performance on diverse benchmarks. Applied to 8,657 tumor samples across 32 cancer types in The Cancer Genome Atlas, CHASMplus identifies over 4,000 unique driver missense mutations in 240 genes, supporting a prominent role for rare driver mutations. We show which TCGA cancer types are likely to yield discovery of new driver missense mutations by additional sequencing, which has important implications for public policy. SignificanceMissense mutations are the most frequent mutation type in cancers and the most difficult to interpret. While many computational methods have been developed to predict whether genes are cancer drivers or whether missense mutations are generally deleterious or pathogenic, there has not previously been a method to score the oncogenic impact of a missense mutation specifically by cancer type, limiting adoption of computational missense mutation predictors in the clinic. Cancer patients are routinely sequenced with targeted panels of cancer driver genes, but such genes contain a mixture of driver and passenger missense mutations which differ by cancer type. A patients therapeutic response to drugs and optimal assignment to a clinical trial depends on both the specific mutation in the gene of interest and cancer type. We present a new machine learning method honed for each TCGA cancer type, and a resource for fast lookup of the cancer-specific driver propensity of every possible missense mutation in the human exome.

bioinformatics↗

bioRxiv2017

CRAVAT 4: Cancer-Related Analysis of Variants Toolkit

Cancer sequencing studies are increasingly comprehensive and well-powered, returning long lists of somatic mutations that can be difficult to sort and interpret. Diligent analysis and quality control can require multiple computational tools of distinct utility and producing disparate output, creating additional challenges for the investigator. The Cancer-Related Analysis of Variants Toolkit (CRAVAT) is an evolving suite of informatics tools for mutation interpretation that includes mutation projecting and quality control, impact prediction and extensive annotation, gene- and mutation-level interpretation including joint prioritization of all nonsilent consequence types, and structural and mechanistic visualization. Results from CRAVAT submissions are explored in an interactive, user-friendly web-environment with dynamic filtering and sorting designed to highlight the most informative mutation, even in the context of very large studies. CRAVAT can be run on a public web-portal, in the cloud, or downloaded for local use, and is easily integrated with other methods for cancer omics analysis.\n\nConflict of interestAll authors declare no potential conflict of interest.

bioinformatics↗

bioRxiv2017

Prediction of peptide binding to MHC Class I proteins in the age of deep learning

Binding of peptides to Major Histocompatibility Complex (MHC) proteins is a critical step in immune response. Peptides bound to MHCs are recognized by CD8+ (MHC Class I) and CD4+ (MHC Class II) T-cells. Successful prediction of which peptides will bind to specific MHC alleles would benefit many cancer immunotherapy appications. Currently, supervised machine learning is the leading computational approach to predict peptide-MHC binding, and a number of methods, trained using results of binding assays, have been published. Many clinical researchers are dissatisfied with the sensitivity and specificity of currently available methods and the limited number of alleles for which they can be applied. We evaluated several recent methods to predict peptide-MHC Class I binding affinities and a new method of our own design (MHCnuggets). We used a high-quality benchmark set of 51 alleles, which has been applied previously. The neural network methods NetMHC, NetMHCpan, MHCflurry, and MHCnuggets achieved similar best-in-class prediction performance in our testing, and of these methods MHCnuggets was significantly faster. MHCnuggets is a gated recurrent neural network, and the only method to our knowledge which can handle peptides of any length, without artificial lengthening and shortening. Seventeen alleles were problematic for all tested methods. Prediction difficulties could be explained by deficiencies in the training and testing examples in the benchmark, suggesting that biological differences in allele-specific binding properties are not as important as previously claimed. Advances in accuracy and speed of computational methods to predict peptide-MHC affinity are urgently needed. These methods will be at the core of pipelines to identify patients who will benefit from immunotherapy, based on tumor-derived somatic mutations. Machine learning methods, such as MHCnuggets, which efficiently handle peptides of any length will be increasingly important for the challenges of predicting immunogenic response for MHC Class II alleles.\n\nAuthor SummaryMachine learning methods are a popular approach for predicting whether a peptide will bind to Major Histocompatibility Complex (MHC) proteins, a critical step in activation of cytotoxic T-cells. The input to these methods is a peptide sequence and an MHC allele of interest, and the output is the predicted binding affinity. MHC Class I and II proteins bind peptides of 8-11 amino acids and 16-26 amino acids respectively. This has been an obstacle for machine learning, because the methods used to date can only handle fixed-length inputs. We show that a recently developed technique known as gated recurrent neural networks can handle peptides of variable length and predict peptide-MHC binding as well or better than existing methods, at substantially faster speeds. Our results have implications for the hundreds of MHC alleles that cannot be predicted with current methods.

bioinformatics↗